Loss-Making CytoTools AG (ETR:T5O) Expected To Breakeven In The Medium-Term

With the business potentially at an important milestone, we thought we'd take a closer look at CytoTools AG's (ETR:T5O) future prospects. CytoTools AG, a biotechnology company, develops a pipeline of disease modifying therapies. The company’s loss has recently broadened since it announced a €1.3m loss in the full financial year, compared to the latest trailing-twelve-month loss of €1.4m, moving it further away from breakeven. As path to profitability is the topic on CytoTools' investors mind, we've decided to gauge market sentiment. In this article, we will touch on the expectations for the company's growth and when analysts expect it to become profitable.

See our latest analysis for CytoTools

CytoTools is bordering on breakeven, according to the 3 German Biotechs analysts. They expect the company to post a final loss in 2021, before turning a profit of €500k in 2022. The company is therefore projected to breakeven just over a year from today. How fast will the company have to grow each year in order to reach the breakeven point by 2022? Working backwards from analyst estimates, it turns out that they expect the company to grow 71% year-on-year, on average, which is extremely buoyant. Should the business grow at a slower rate, it will become profitable at a later date than expected.

Given this is a high-level overview, we won’t go into details of CytoTools' upcoming projects, though, keep in mind that by and large biotechs, depending on the stage of product development, have irregular periods of cash flow. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

Before we wrap up, there’s one aspect worth mentioning. CytoTools currently has no debt on its balance sheet, which is quite unusual for a cash-burning biotech, which usually has a high level of debt relative to its equity. This means that the company has been operating purely on its equity investment and has no debt burden. This aspect reduces the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of CytoTools to cover in one brief article, but the key fundamentals for the company can all be found in one place – CytoTools' company page on Simply Wall St. We've also put together a list of essential factors you should further research:

1. Valuation: What is CytoTools worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether CytoTools is currently mispriced by the market.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on CytoTools’s board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

If you decide to trade CytoTools, use the lowest-cost* platform that is rated #1 Overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.